SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Focused Visit (Follow-up) — Evel Knievel — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientEvel Knievel
Date of birth1938-10-17
IdentifiersMRN HR-RB001-SYN-TD; SSN (made up) 000-01-4927
Document date1996-05-18
AuthorDale Rasmussen, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

End of 12 weeks of hepatitis C treatment. [S]

History of Present Illness

Mr. Knievel finished sofosbuvir-velpatasvir yesterday without missing a dose. He has had no alcohol since the day treatment started. He takes carvedilol 12.5 mg daily without dizziness. His glucose sensor has shown no readings below 70 mg/dL. The bone density scan ten weeks ago showed osteoporosis at the hip. He has had no falls since starting physical therapy, walks 20 minutes on flat ground and swims twice a week; pain is about 4 of 10. He has not yet had his diabetic eye examination because the appointment was not booked after the referral. He saw his dentist last week. He has had no muscle aches, abdominal swelling, black stools, confusion or yellow eyes. He has had no thoughts of self-harm. [S]

ElementDetail
Treatment12 weeks of sofosbuvir-velpatasvir completed; no missed doses
AlcoholNone for 12 weeks
Bone densityFemoral neck T-score -2.6; lumbar spine -1.9
Glucose sensorGlucose management indicator 6.9%; no lows
Eye examinationNot yet done

Review of Systems

SystemResultFinding
ConstitutionalNegativeMore energy; weight down 1.6 kg
GastrointestinalNegativeNo abdominal swelling, black stools or nausea
MusculoskeletalPositiveHip and knee pain, 4 of 10; no muscle aches
EndocrineNegativeNo low glucose readings
NeurologicalNegativeNo confusion or tremor
PsychiatricNegativeMood good; PHQ-9 4; no thoughts of self-harm

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Metformin 1000 mg oral tablet, one tablet by mouth twice daily with mealsOne tablet twice daily with breakfast and supperOral route1991-03-01activeS
Ibuprofen 800 mg oral tablet, one tablet three times a day for joint and back painOne tablet three times a dayOral route1994-06-01 to 1996-01-12completedS
Omeprazole 20 mg delayed-release oral capsule, one capsule daily for indigestion from ibuprofenOne capsule daily before breakfastOral route1994-06-01 to 1996-01-12completedS
Acetaminophen 500 mg oral tablet, two tablets by mouth up to twice a day as needed for pain, no more than 2 g a dayTwo tablets up to twice a day as needed; no more than 2 g a dayOral route1996-01-12activeS
Diclofenac sodium 1% topical gel, 4 g to the knees up to four times a day4 g to each knee up to four times a dayTopical route1996-01-12activeS
Carvedilol 6.25 mg oral tablet, one tablet dailyOne tablet dailyOral route1996-01-26 to 1996-02-23completedS
Carvedilol 12.5 mg oral tablet, one tablet dailyOne tablet dailyOral route1996-02-23activeS
Atorvastatin 20 mg oral tablet, one tablet dailyOne tablet dailyOral route1996-01-26activeS
Sofosbuvir 400 mg and velpatasvir 100 mg oral tablet, one tablet daily for 12 weeksOne tablet daily for 12 weeksOral route1996-02-23 to 1996-05-17completedS
Cholecalciferol (vitamin D3) 50 mcg (1970 units) oral capsule, one capsule dailyOne capsule dailyOral route1996-02-23activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1996-05-18Body height178cmS
1996-05-18Body weight83.2kgS
1996-05-18Body mass index (BMI) [Ratio]26.3kg/m2S
1996-05-18Systolic blood pressure118mm[Hg]S
1996-05-18Diastolic blood pressure72mm[Hg]S
1996-05-18Heart rate62/minS
1996-05-18Respiratory rate14/minS
1996-05-18Body temperature36.5CelS
1996-05-18Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1996-05-18Hemoglobin [Mass/volume] in Blood14.2g/dL13.5-17.5 g/dLNormalS
1996-05-18Leukocytes [#/volume] in Blood by Automated count510*3/uL4-11 10*3/uLNormalS
1996-05-18Platelets [#/volume] in Blood by Automated count12910*3/uL150-400 10*3/uLLowS
1996-05-18Creatinine [Mass/volume] in Serum or Plasma0.89mg/dL0.74-1.35 mg/dLNormalS
1996-05-18Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1991)/1.73 sq M100mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1996-05-18Glucose [Mass/volume] in Serum or Plasma118mg/dL70-99 mg/dLHighS
1996-05-18Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma24U/L7-55 U/LNormalS
1996-05-18Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma29U/L8-48 U/LNormalS
1996-05-18Bilirubin.total [Mass/volume] in Serum or Plasma0.8mg/dL0.1-1.2 mg/dLNormalS
1996-05-18Albumin [Mass/volume] in Serum or Plasma3.9g/dL3.5-5 g/dLNormalS
1996-05-18Calcium [Mass/volume] in Serum or Plasma9.3mg/dL8.6-10.3 mg/dLNormalS
1996-05-18Hepatitis C virus RNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection0[IU]/mLNot detected is reported as 0; lower limit of quantification 15 IU/mLNormalS
1996-05-18Hemoglobin A1c/Hemoglobin.total in Blood6.4%Below 5.7% is normal; individual goal below 7%; may read falsely low in cirrhosisHighS
1996-05-18Glucose management indicator6.9%Individual goal below 7%NormalS
1996-05-1825-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma34ng/mL30-100 ng/mLNormalS
1996-05-18Parathyrin.intact [Mass/volume] in Serum or Plasma48pg/mL15-65 pg/mLNormalS
1996-05-18Testosterone [Mass/volume] in Serum or Plasma455ng/dL264-916 ng/dLNormalS
1996-05-18Total score [AUDIT-C]0{score}S
1996-05-18Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S
1996-05-18Pain severity - 0-10 verbal numeric rating [Score] - Reported4{score}S

Physical Exam

Vital signs recorded on 1996-05-18; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 83.2 kg; blood pressure 118/72, pulse 62
SkinSpider angiomas fewer; no jaundice
AbdomenSpleen tip palpable; no ascites
MouthTeeth in good repair
NeurologicalNo asterixis; gait steady with a cane

Problems

ProblemClinical statusVerificationCodeProvenance
Raised transaminases (ALT 88, AST 96 U/L) and low platelets (118) on today's tests, with spider angiomas and palmar erythema, in a man of 57 who received many blood transfusions after crashes before 1962 and drinks most evenings: chronic liver disease, most likely hepatitis C, must be excluded. Hepatitis C antibody with reflex RNA, hepatitis A and B serology, HIV, liver ultrasound and hepatology review orderedresolvedconfirmed R74.01S — Synthetic presenting problem; no symptom or result of his real illness was made public. Superseded at the hepatology consultation.
Chronic hepatitis C, genotype 1a, treatment-naive, HCV RNA 2.35 million IU/mL, likely acquired through blood transfusions after crashes; synthetic modern detail linked to his publicly reported transfusion-acquired hepatitis Cactiveconfirmed B18.2S — Synthetic genotype, viral load and timing; his hepatitis C and its likely transfusion source are documented (D).
Compensated cirrhosis from hepatitis C, with alcohol as a cofactor: liver stiffness 26.8 kPa, FIB-4 4.94, nodular liver and a 14.2 cm spleen on ultrasound, platelets 118; Child-Pugh A5, MELD-Na 8; no ascites, encephalopathy, jaundice or bleedingactiveconfirmed K74.69S — Synthetic stage of liver disease linked to his documented hepatitis C and later liver transplant.
Clinically significant portal hypertension in compensated cirrhosis (liver stiffness 25 kPa or more), treated with carvedilol without screening endoscopy (Baveno VII)activeconfirmed K76.6S — Synthetic finding at the hepatology consultation.
Type 2 diabetes on metformin, A1c 7.4%activeconfirmed E11.65S — Synthetic; diabetes is documented only in his last years (D), and placing it at 57 is a synthetic choice.
Chronic pain in the back, hips, pelvis and knees after dozens of fractures from stunt crashes, including a broken pelvis; ibuprofen stopped, and managed without oral NSAIDs or opioidsactiveconfirmed G89.29S — Synthetic pain at the index age, anchored to his documented fractures and the pain of his later years.
Osteoporosis in a man with cirrhosis, prior heavy alcohol use and dozens of old fractures: femoral neck T-score -2.6, lumbar spine -1.9activeconfirmed M81.8S — Synthetic bone density result.
Vitamin D deficiency (25-hydroxyvitamin D 17 ng/mL)resolvedconfirmed E55.9S — Synthetic finding before the bone density scan.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryHCV RNA at the end of treatmentOptional at the end of treatmentCompleted todayNot detected
LaboratoryHepatic function panel, blood count and kidney functionAt the end of treatment in cirrhosis, as neededCompleted todayALT 24, AST 29 U/L, bilirubin 0.8 mg/dL, albumin 3.9 g/dL; platelets 129, hemoglobin 14.2 g/dL, white cells 5.0; creatinine 0.89 mg/dL, eGFR 100
Medication safetyAdherence and side effectsDuring treatmentCompleted todayNo missed doses; no side effects; no muscle aches on atorvastatin
LaboratoryGlucose control in cirrhosis: A1c with sensor dataEvery three months when therapy changesCompleted todayA1c 6.4%; glucose management indicator 6.9%; fasting glucose 118 mg/dL; no hypoglycemia
ReferralDiabetic eye examinationYearlyDeferredA deviation: referred two visits ago but never booked, because the referral was sent without an appointment request. No harm is known; he has no visual symptoms. Corrective action: booked today for next month, with a reminder to confirm the result
ImagingBone density (DXA)Men at riskUp to dateTen weeks ago: femoral neck T-score -2.6, lumbar spine -1.9; FRAX hip fracture risk 4.1%
LaboratorySecondary causes of osteoporosis and calcium before zoledronic acidBefore starting treatmentCompleted todayVitamin D 34 ng/mL, calcium 9.3 mg/dL, parathyroid hormone 48 pg/mL, testosterone 455 ng/dL
Medication safetyDental review before a bisphosphonateBefore the first doseUp to dateSeen by his dentist last week
Medication safetyCarvedilol: blood pressure and heart rateEach visitCompleted today118/72, pulse 62
ImagingLiver ultrasound for cancer surveillanceEvery six months in cirrhosisDueDue in July, six months after the baseline scan
ExaminationSigns of decompensation (ascites, encephalopathy, jaundice, bleeding)Each visit in cirrhosisCompleted todayNone
Self-managementFalls and fracture riskEach visitCompleted todayNo falls since physical therapy; cane outdoors
SurveyAlcohol use (AUDIT-C)Each visit in liver diseaseCompleted todayAUDIT-C 0
SurveyPain score and functionEach visitCompleted today4 of 10
SurveyDepression screen (PHQ-9)At diagnosis and when treatment changesCompleted todayPHQ-9 4

Goal progress:

Guideline basis: AASLD-IDSA HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Simplified HCV treatment algorithm for treatment-naive adults with compensated cirrhosis (2023); AASLD-IDSA HCV Guidance: Monitoring patients who are starting HCV treatment, are on treatment, or have completed therapy (2026); EPCLUSA (sofosbuvir and velpatasvir) tablets, prescribing information (2025); Singal AG, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 2023;78(6):1922-1965 (PMID 37199193) (2023); de Franchis R, et al. Baveno VII - Renewing consensus in portal hypertension. J Hepatol 2022;76(4):959-974 (PMID 35120736) (2022); Kaplan DE, et al. AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology 2024;79(5):1180-1211 (PMID 37870298) (2024); Biggins SW, et al. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the AASLD. Hepatology 2021;74(2):1014-1048 (PMID 33942342) (2021); Crabb DW, et al. Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the AASLD. Hepatology 2020;71(1):306-333 (PMID 31314133) (2019); Rakoski M, Goyal P, Spencer-Safier M, et al. Pain management in patients with cirrhosis. Clin Liver Dis (Hoboken) 2018;11(6):135-140 (PMID 30992804) (2018); Dowell D, et al. CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022. MMWR Recomm Rep 2022;71(3):1-95 (PMID 36327391) (2022); American Diabetes Association. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2026. Diabetes Care 2026;49(Suppl 1):S61-S88 (PMID 41358897) (2026); American Diabetes Association. 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. Diabetes Care 2026;49(Suppl 1):S132-S149 (PMID 41358894) (2026); Watts NB, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012;97(6):1802-1822 (PMID 22675062) (2012); Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions (2018); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, osteoporosis and depression monographs (2026); Depression and Suicide Risk in Adults: Screening (2023)

Follow-up: Zoledronic acid infusion in two weeks. Eye examination next month. Liver ultrasound in July. Review with HCV RNA, liver tests and alpha-fetoprotein 12 or more weeks after the last dose. Next scheduled visit 1996-08-17: cure confirmed (SVR12): six-month liver cancer surveillance, cirrhosis care after cure, and transplant criteria reviewed. [S]